BLR Bio combines a strong history and current activity in basic and molecular biology, biochemistry, applied drug development and clinical fields. Each facilitate the other for optimum results.
We focus on how the cell interacts with other cells and its surrounding micro- and macro-environments in response to injury/stress and how this is translated either normal wound healing or to impaired cell and organ function / disfunction (disease).
We create long-term partnerships with top international institutes and experts to maximize the creativity, breath, and speed of our drug discovery and development process providing:
These relationships allow our company to work and to achieve at levels equal to, or better, than many larger organizations.
Our focus is on fibro-inflammatory disease and cancer within areas of the high medical need including orphan diseases and in some cases select diseases affecting larger populations.
Supporting our therapeutic activities, we also have a paired diagnostic biomarker program that will provide unique opportunities in personalized medicine in these target diseases.
Our next-generation therapeutics are designed to transform patient outcomes in diseases of high unmet medical needs. BLR Bio is a privately held biotechnology company committed to the discovery and development of transformational therapeutics that combine the best features of both biologic and small molecule drug classes into easy to manufacture and deliver, small peptides with high target specificity.